Poliklinika Ginekologiczno-Położniczasp. z o.o.
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2013-02-06
Share capital
5,000.00 PLN
Registered address
Zamenhofa 19, 15-435 Białystok, Poland
Electronic delivery address
AE:PL-42895-42824-JIEWA-22
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 89 days late).
- 202502/07/2026
- 202414/07/2025
- 202321/06/2024
- 202223/06/2023
- 202112/10/2022
- 202013/10/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations199 / 231
Top 86%
Results vs industry
Revenue
This companyUSD 12.03kMedianUSD 165.97kAverageUSD 2.30m
Net profit
This companyUSD 11.74kMedianUSD 1.32kAverageUSD 109.80k
Operating costs
This companyUSD 292.89MedianUSD 201.81kAverageUSD 2.10m
Assets
This companyUSD 12.77kMedianUSD 118.27kAverageUSD 1.54m
Industry
Authorized Representatives
Krzysztof Arciszewski – President of the Management Board
Bartosz Piotr Kasprzak – Attorney-in-fact (sole)
Manner of representation
In the case of a multi-member management board, the President of the Management Board independently, two members of the management board jointly, or a member of the management board jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Krzysztof Arciszewskiage 70 | 100 | $1,350.62 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Debt
No entries in the National Debtors Register (KRZ).
Public aid
No public aid cases recorded in the last 10 years.
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2022-09-21 | Implementation of a design strategy as an opportunity for the development of the gynaecological and obstetric polyclinic | $226.4K$226,378 | Operational Programme Eastern Poland |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Natur DayS.A. | $680,635.59 | naturday.pl | ||
| Biotriosp. z o.o. | $453,662.22 | biotrio.pl | ||
| Nature's Voicesp. z o.o. | $181,977.76 | naturesvoice.eu | ||
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| Bioresearch PharmaS.A. | $21,432.15 | bioresearchpharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Grupa FinepharmS.A. | – | finepharm.pl | ||
| Dobre Zdrowiesp. z o.o. | – | dobrezdrowie.eu |
FAQ
The company was registered in the Polish National Court Register (KRS) on February 6, 2013.
The headquarters is located at: Zamenhofa 19, 15-435 Białystok.
The management board includes Krzysztof Arciszewski (President of the Management Board).
The share capital of the company is PLN 5,000 (approx. $1,351).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $1,503 in 2024.
Yes, in 2024 the company was profitable, achieving a net profit of $988.
The largest operating cost category falls under external services. This category amounted to $265 in 2024, representing 51% of all operating expenses.
Last updated: 2026-10-07